Effects of GLP1-RA on Ectopic Fat Deposition in Chronic Kidney Disease

NCT05254418 on ClinicalTrials.gov · last registry update 2025-04-20

A small phase 2 — 7 participants, against a typical 110. The sponsor logged completion for 1 May 2024. Primary outcome, as filed: Changes in Intermuscular Fat Deposition as Assessed by Magnetic Resonance Imaging (MRI). dulaglutide is approved in the US, but not for chronic kidney disease — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P2
Drug: dulaglutide
Trulicity
Sponsor: Vanderbilt University Medical Center
Sponsor type: Other
Enrollment: 7
Started: 2022-03-15
Primary completion: 2024-05-01 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Changes in Intermuscular Fat Deposition as Assessed by Magnetic Resonance Imaging (MRI).

Conditions studied

Chronic Kidney Diseases

Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.